These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33766125)

  • 1. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
    Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
    Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentration of asprosin in new-onset type 2 diabetes.
    Naiemian S; Naeemipour M; Zarei M; Lari Najafi M; Gohari A; Behroozikhah MR; Heydari H; Miri M
    Diabetol Metab Syndr; 2020; 12():65. PubMed ID: 32714446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of asprosin and Nrg-4 with type 2 diabetes Mellitus Complicated with Coronary Heart Disease and the Diagnostic Value.
    Zhong M; Tian X; Sun Q; Li L; Lu Y; Feng Z; Gao Y; Li S
    BMC Endocr Disord; 2023 Mar; 23(1):61. PubMed ID: 36915073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
    Dai C; Zhu W
    Medicine (Baltimore); 2022 Oct; 101(43):e31334. PubMed ID: 36316938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
    Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A
    Cardiovasc Diabetol; 2017 Apr; 16(1):42. PubMed ID: 28376855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial.
    Yan X; Ma J; Liu Y; Wang X; Li S; Yan S; Mo Z; Zhu Y; Lin J; Liu J; Jia Y; Liu L; Ding K; Xu M; Zhou Z
    Lancet Reg Health West Pac; 2024 Jun; 47():101101. PubMed ID: 38948164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
    Kaku K; Inoue S; Matsuoka O; Kiyosue A; Azuma H; Hayashi N; Tokudome T; Langkilde AM; Parikh S
    Diabetes Obes Metab; 2013 May; 15(5):432-40. PubMed ID: 23194084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.
    Wang Y; Xu L; Yuan L; Li D; Zhang Y; Zheng R; Liu C; Feng X; Li Q; Li Q; Ma J
    Diabet Med; 2016 Dec; 33(12):1732-1736. PubMed ID: 26927445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.
    Yang Y; Chen S; Pan H; Zou Y; Wang B; Wang G; Zhu H
    Medicine (Baltimore); 2017 May; 96(21):e6944. PubMed ID: 28538386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
    Kwak SH; Han KA; Kim KS; Yu JM; Kim E; Won JC; Kang JG; Chung CH; Oh S; Choi SH; Won KC; Kim SG; Cho SA; Cho BY; Park KS
    Diabetes Obes Metab; 2023 Jul; 25(7):1865-1873. PubMed ID: 36872067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus.
    Talebi SS; Rezaie S; Hajmiri MS; Zamanirafe M; Ranjbar A; Moridi H; Mirjalili M; Mehrpooya M
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Nov; 397(11):9149-9165. PubMed ID: 38900252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
    Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.